Explore the vast range of titles available.

Under what conditions of supply and demand are experts likely to give us good advice? When is expert failure more likely? Do entrepreneurs challenge existing expertise? Are they experts themselves? This title brings a heterogeneous collection of thinkers, some \"Austrian\" and to engage the problem of experts.

Abstract Background The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV. Patients and Methods We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients. Results Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression <10%, including 60 (21.8%) with undetectable CD30 by IHC. No significant differences were observed for any study in overall response rates between patients with CD30 expression ≥10% or <10%. Median duration of response was also similar in the CD30 ≥10% and <10% groups for all studies. Conclusions In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain. The safety and efficacy of brentuximab vedotin, an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with lymphoma. This article examines the relationship between CD30 expression level and clinical response to brentuximab vedotin.

I argue that the economics of Hayek and Keynes diverges most significantly not with respect to policy but in their understanding of the role of capital in a market economy, and how capital relates to issues of savings and investment. Specifically, Hayek's Austrian conception of capital provides a different, and very disaggregated, vision of the market process that can help identify the flaws in Keynesian theory and policy. Hayek's view of capital forces the economist to consider the microeconomic foundations of macroeconomic phenomena in a way that validates Hayek's complaint that Keynes's aggregates conceal the fundamental mechanisms of change.